The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral atypical antipsychotics (e.g., Otsuka / Lundbeck’s Rexulti and Allergan / Gedeon Richter / Recordati’s Vraylar / Reagila), and the intensifying competition among long-acting injectables (LAIs). Indeed, to gain a foothold in the market, differentiation from already established therapies is a primary requirement for late-phase and recently approved therapies—including new oral atypical antipsychotics (e.g., Alkermes’s ALKS 3831), new LAIs (e.g., Indivior’s Perseris, Janssen’s paliperidone six-month depot, Teva’s TV-46000), and others (e.g., Intra-Cellular Therapies’ lumateperone, Minerva Neurosciences’ roluperidone, and Sunovion / Sumitomo Dainippon Pharma’s SEP-363856). Meanwhile, the potential of early- to mid-phase therapies for negative symptoms and cognitive impairment associated with schizophrenia, which are symptoms on which drug developers are increasingly focusing, remains to be seen.
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What factors drive and constrain the use of LAIs of atypical antipsychotics? How is competition heating up in this segment?
- What are the biggest areas of unmet need? What is the line-up of late-phase emerging therapies with the potential to fulfill these needs?
- What would key late-phase emerging therapies need to demonstrate to compete effectively in this crowded market?
Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Geographies: United States, EU5, Japan.
Primary research: 35 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms and negative symptoms; drug-treated prevalence of schizophrenia by country.
Forecast: Ten-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2028, segmented by brands / generics.
Emerging therapies: Phase III / PR: 8 drugs. Coverage of select Phase II and Phase I products.